{
  "meta": {
    "title": "Liver_Disease_Part_2",
    "url": "https://brainandscalpel.vercel.app/liver-disease-part-2-469e9890.html",
    "scrapedAt": "2025-11-30T08:49:11.399Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Start ursodeoxycholic acid (UDCA).</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Order an MRCP to evaluate for biliary strictures.</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Perform a liver biopsy to confirm the diagnosis.</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Prescribe cholestyramine for symptom relief.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old woman presents with fatigue and pruritus. Her liver function tests reveal the following:<ul> <li><strong>Bilirubin:</strong> 1.2 mg/dL</li> <li><strong>Alkaline phosphatase:</strong> Elevated</li> <li><strong>AST/ALT:</strong> Normal</li> <li><strong>GGT:</strong> Elevated</li> </ul>An ultrasound of the abdomen reveals no bile duct dilation. Antimitochondrial antibodies (AMA) are positive. What is the most appropriate next step in the management of this patient?</span></p>",
      "unique_key": "DT1295030",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295030,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Clinical Context:</strong>\r\n<ul>\r\n<li>Elevated alkaline phosphatase and GGT with positive AMA and normal AST/ALT are diagnostic of <strong>Primary Biliary Cholangitis (PBC)</strong>.</li>\r\n<li>Absence of bile duct dilation on imaging rules out extrahepatic obstruction.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Next Step:</strong>\r\n<ul>\r\n<li>Ursodeoxycholic acid (UDCA) is the first-line treatment for PBC. It improves liver biochemistry, delays disease progression, and enhances survival.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Options:</strong>\r\n<ul>\r\n<li><strong>B. Order an MRCP:</strong> MRCP is not necessary as ultrasound showed no bile duct dilation, and AMA positivity confirms the diagnosis.</li>\r\n<li><strong>C. Liver Biopsy:</strong> Biopsy is not required if the clinical and serological findings are diagnostic (e.g., AMA positivity with cholestatic pattern).</li>\r\n<li><strong>D. Cholestyramine:</strong> While effective for pruritus management, it does not address the underlying disease and should not replace UDCA as the primary treatment.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Primary Biliary Cholangitis (PBC):</strong> Characterized by cholestatic liver biochemistry and AMA positivity.</li>\r\n<li><strong>First-line Therapy:</strong> UDCA improves outcomes and delays the need for liver transplantation.</li>\r\n<li><strong>Symptom Management:</strong> Cholestyramine can be added for pruritus but does not treat the underlying disease.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501068c53ebd2-4241-4023-89af-d99fb4de6cf6.jpg\">\r\n",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Dubin-Johnson syndrome</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Gilbert's syndrome</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary biliary cholangitis (PBC)</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Hemolysis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 35-year-old woman presents with fatigue and jaundice. Laboratory tests reveal the following:<ul><li>Total bilirubin: 4.5 mg/dL (normal: 0.3&ndash;1.2 mg/dL)</li><li>Direct bilirubin: 0.5 mg/dL</li><li>ALT, AST, and alkaline phosphatase are within normal limits.</li><li>Peripheral blood smear: No evidence of hemolysis.</li></ul>Which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295122",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295122,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Key Clinical Features:</strong>\r\n<ul>\r\n<li>Isolated indirect hyperbilirubinemia with normal liver enzymes is characteristic of <strong>Gilbert's syndrome</strong>.</li>\r\n<li>Absence of hemolysis (normal smear) and normal direct bilirubin levels confirm that the hyperbilirubinemia is unconjugated.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Pathophysiology of Gilbert&rsquo;s Syndrome:</strong>\r\n<ul>\r\n<li>Caused by reduced activity of <strong>UDP-glucuronosyltransferase</strong>, leading to impaired bilirubin conjugation.</li>\r\n<li>Triggered by fasting, stress, or illness.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Options:</strong>\r\n<ul>\r\n<li><strong>Dubin-Johnson Syndrome (A):</strong> Associated with conjugated hyperbilirubinemia and darkly pigmented liver on biopsy.</li>\r\n<li><strong>Primary Biliary Cholangitis (C):</strong> Causes cholestatic liver disease with elevated alkaline phosphatase and antimitochondrial antibodies (AMA).</li>\r\n<li><strong>Hemolysis (D):</strong> Would present with indirect hyperbilirubinemia and findings such as anemia or reticulocytosis on a peripheral smear.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Diagnostic Approach from Flowchart:</strong>\r\n<ul>\r\n<li>Fractionated bilirubin &gt;85% indirect &rarr; Evaluate for hemolysis or Gilbert&rsquo;s syndrome.</li>\r\n<li>Workup negative for hemolysis confirms Gilbert&rsquo;s syndrome.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Diagnostic Workup</strong></p>\r\n<p>To determine the source of elevated ALP, follow this structured approach:</p>\r\n<ol>\r\n<li><strong>Fractionate ALP:</strong>\r\n<ul>\r\n<li>Use tests like gamma-glutamyl transpeptidase (GGT) or 5'-nucleotidase to confirm the liver origin of ALP:\r\n<ul>\r\n<li><strong>Liver Origin:</strong> Elevated GGT/5&rsquo;-nucleotidase.</li>\r\n<li><strong>Bone Origin:</strong> Normal GGT/5&rsquo;-nucleotidase; assess bone markers.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li><strong>Evaluate Clinical Context:</strong>\r\n<ul>\r\n<li><strong>Liver-related Symptoms:</strong> Jaundice, pruritus, or fatigue suggest liver involvement.</li>\r\n<li><strong>Bone-related Symptoms:</strong> Bone pain, fractures, or deformities point to bone origin.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Imaging Studies:</strong>\r\n<ul>\r\n<li><strong>Liver ultrasound or MRCP:</strong> Rule out biliary obstruction or cholestasis.</li>\r\n<li><strong>Bone X-rays or DEXA scan:</strong> Assess for Paget&rsquo;s disease, fractures, or osteopenia.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Specific Laboratory Tests:</strong>\r\n<ul>\r\n<li><strong>AMA (antimitochondrial antibodies):</strong> Suspect PBC.</li>\r\n<li><strong>Serum calcium, phosphate, and vitamin D:</strong> Evaluate bone metabolism.</li>\r\n<li><strong>Thyroid function tests:</strong> Rule out hyperthyroidism.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Isolated indirect hyperbilirubinemia with normal liver function tests points to <strong>Gilbert&rsquo;s syndrome</strong>.</li>\r\n<li>Diagnostic confirmation is based on clinical history and exclusion of other causes.</li>\r\n<li>It is a benign, hereditary condition that requires no treatment.</li>\r\n</ul>\r\n",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Score: 8, Class B</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Score: 10, Class C</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Score: 7, Class B</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Score: 9, Class B</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 58-year-old male with known chronic liver disease (CLD) is admitted for evaluation. His laboratory and clinical findings are as follows:<ul><li>Serum bilirubin: 3.5 mg/dL</li><li>Serum albumin: 2.8 g/dL</li><li>Prothrombin time prolongation (INR): 2.2</li><li>Ascites: Easily controlled with diuretics</li><li>Hepatic encephalopathy: Minimal</li></ul>Based on the Child-Turcotte-Pugh (CTP) scoring system, what is his CTP score, and what is his class?</span></p>",
      "unique_key": "DT1295127",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295127,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Using the Child-Turcotte-Pugh (CTP) scoring system:</p>\r\n<ol>\r\n<li><strong>Serum Bilirubin (3.5 mg/dL):</strong>\r\n<ul>\r\n<li>Score = <strong>2</strong> (34-51 &mu;mol/L or 2.0-3.0 mg/dL scores 2 points).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Serum Albumin (2.8 g/dL):</strong>\r\n<ul>\r\n<li>Score = <strong>2</strong> (30-35 g/L or 3.0-3.5 g/dL scores 2 points).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Prothrombin Time (INR 2.2):</strong>\r\n<ul>\r\n<li>Score = <strong>2</strong> (INR 1.7-2.3 scores 2 points).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Ascites (Easily controlled):</strong>\r\n<ul>\r\n<li>Score = <strong>2</strong> (Easily controlled scores 2 points).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Hepatic Encephalopathy (Minimal):</strong>\r\n<ul>\r\n<li>Score = <strong>2</strong> (Minimal encephalopathy scores 2 points).</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Total Score = 2 + 2 + 2 + 2 + 2 = 8.</strong></p>\r\n<p><strong>Interpretation:</strong></p>\r\n<p>The <strong>Child-Turcotte-Pugh (CTP) score</strong> is a clinical tool used to assess the severity of <strong>chronic liver disease</strong> (particularly cirrhosis) and to predict prognosis. It evaluates liver function based on <strong>five parameters</strong>.</p>\r\n<p><strong>CTP Parameters</strong></p>\r\n<p>The score incorporates <strong>three laboratory tests</strong> and <strong>two clinical findings</strong>:</p>\r\n<ol>\r\n<li><strong>Serum Bilirubin</strong> (reflects hepatobiliary function and severity of jaundice).</li>\r\n<li><strong>Serum Albumin</strong> (reflects liver synthesis function).</li>\r\n<li><strong>Prothrombin Time (INR)</strong> (indicates coagulopathy due to impaired liver synthesis of clotting factors).</li>\r\n<li><strong>Ascites</strong> (presence and severity indicate decompensation).</li>\r\n<li><strong>Hepatic Encephalopathy</strong> (severity reflects ammonia clearance impairment).</li>\r\n</ol>\r\n<p><strong>Scoring</strong></p>\r\n<p>Each parameter is graded from <strong>1 to 3 points</strong> based on severity:</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106527aad28-0d3e-4671-8ed3-42b505404bc1.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>CTP scoring evaluates the severity of liver disease and is used to assess prognosis and prioritize liver transplantation.</li>\r\n<li><strong>Class A (Score 5-6):</strong> Well-compensated cirrhosis.</li>\r\n<li><strong>Class B (Score 7-9):</strong> Significant functional compromise.</li>\r\n<li><strong>Class C (Score &ge;10):</strong> Decompensated liver disease with poor prognosis.</li>\r\n</ul>\r\n<p>The <strong>Child-Turcotte-Pugh (CTP) score</strong> is a clinical tool used to assess the severity of <strong>chronic liver disease</strong> (particularly cirrhosis) and to predict prognosis. It evaluates liver function based on <strong>five parameters</strong>.</p>\r\n",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Perform a liver biopsy to assess fibrosis.</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Initiate weight loss and lifestyle modifications.</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Prescribe ursodeoxycholic acid.</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Order a computed tomography (CT) scan for further fat quantification.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 58-year-old man visits your clinic after an abdominal ultrasound performed for nonspecific abdominal discomfort reveals Grade 1 fatty liver. He has no significant symptoms, and his physical examination is unremarkable. His past medical history includes type 2 diabetes and hypertension, and he has a BMI of 32 kg/m2. Laboratory tests reveal normal ALT, AST, and alkaline phosphatase levels.<br>Which of the following is the most appropriate next step in managing this patient?</span></p>",
      "unique_key": "DT1295132",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295132,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Interpretation of Grade 1 Fatty Liver:</strong>\r\n<ul>\r\n<li>Grade 1 fatty liver on ultrasound is a common finding, particularly in patients with obesity, diabetes, or metabolic syndrome.</li>\r\n<li>It usually represents <strong>simple steatosis</strong>, which has a low risk of progression without additional risk factors.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Next Step:</strong>\r\n<ul>\r\n<li>The most effective initial management is <strong>lifestyle modifications</strong>, including dietary changes, increased physical activity, and weight loss (targeting 7-10% of body weight). These interventions improve hepatic steatosis and insulin sensitivity.</li>\r\n<li>Pharmacological treatments, such as ursodeoxycholic acid, are not indicated for simple steatosis.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Options:</strong>\r\n<ul>\r\n<li><strong>A. Liver biopsy:</strong> Reserved for patients with suspected advanced fibrosis or when noninvasive tests are inconclusive. Not appropriate for Grade 1 steatosis.</li>\r\n<li><strong>C. Ursodeoxycholic acid:</strong> Has no proven benefit for nonalcoholic fatty liver disease (NAFLD).</li>\r\n<li><strong>D. CT scan:</strong> Not required as ultrasound is sufficient for the initial evaluation of fatty liver, and CT involves unnecessary radiation exposure.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Grade 1 fatty liver</strong> is best managed with lifestyle changes to address underlying metabolic risk factors.</li>\r\n<li>Noninvasive tools such as FibroScan or MRI may be considered if there is suspicion of advanced disease.</li>\r\n<li>Routine liver biopsy or CT scan is not warranted in asymptomatic cases with normal liver enzymes.</li>\r\n</ul>\r\n",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Isoniazid</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetaminophen</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Methyltestosterone</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs is NOT associated with drug-induced hepatocellular injury?</span></p>",
      "unique_key": "DT1295135",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295135,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Hepatocellular Injury:</strong>\r\n<ul>\r\n<li>Drugs like <strong>isoniazid</strong> and <strong>acetaminophen</strong> are known to cause a hepatocellular pattern of liver damage characterized by elevated ALT and AST.</li>\r\n<li>Acetaminophen, in overdose, causes centrilobular necrosis due to reactive metabolites depleting glutathione.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Methyltestosterone:</strong>\r\n<ul>\r\n<li>Causes <strong>cholestatic injury</strong>, not hepatocellular damage. It impairs bile flow and is commonly associated with jaundice.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Methotrexate:</strong>\r\n<ul>\r\n<li>Causes <strong>microvesicular and macrovesicular steatosis</strong> with long-term use, particularly in patients with underlying liver conditions.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Drug-induced liver injury can present as hepatocellular, cholestatic, or mixed patterns, depending on the drug and mechanism of toxicity.</li>\r\n<li><strong>Methyltestosterone</strong> is associated with cholestatic injury rather than hepatocellular damage.</li>\r\n</ul>\r\n",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Benign postoperative cholestasis</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Cryptosporidiosis</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Extrahepatic biliary obstruction</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Hepatitis A infection</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is NOT a cause of cholestatic syndromes?</span></p>",
      "unique_key": "DT1295145",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295145,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Cholestatic Syndromes:</strong> These are conditions characterized by impaired bile flow, leading to jaundice and elevated cholestatic markers like alkaline phosphatase.\r\n<ul>\r\n<li>Examples include benign postoperative cholestasis, cholestasis of pregnancy, and extrahepatic biliary obstruction.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Cryptosporidiosis:</strong> A parasitic infection affecting the biliary tract, particularly in immunocompromised patients, and a recognized cause of cholestasis.</li>\r\n<li><strong>Hepatitis A Infection:</strong> This is a hepatocellular disease primarily causing acute liver inflammation and does not typically present as a cholestatic syndrome.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Cholestasis results from conditions affecting bile production or flow, either intrahepatic or extrahepatic.</li>\r\n<li>Hepatitis A causes hepatocellular injury, not cholestasis.</li>\r\n</ul>\r\n",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary Biliary Cholangitis (PBC)</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Autoimmune Hepatitis (AIH)</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary Sclerosing Cholangitis (PSC)</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Nonalcoholic Steatohepatitis (NASH)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 38-year-old woman presents with fatigue, right upper quadrant discomfort, and intermittent jaundice. She has a history of hypothyroidism treated with levothyroxine. Laboratory investigations show:<ul><li>ALT: 120 IU/L, AST: 110 IU/L</li><li>Alkaline phosphatase: Normal</li><li>Bilirubin: Normal</li><li>Elevated total protein with hypergammaglobulinemia</li></ul>Autoimmune serologies reveal:<ul><li>Positive antinuclear antibody (ANA) and smooth muscle antibody (SMA)</li><li>Elevated IgG levels</li></ul>What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295169",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295169,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Key Clinical Features of AIH:</strong>\r\n<ul>\r\n<li><strong>Hepatocellular injury:</strong> Elevated ALT and AST levels with normal alkaline phosphatase and bilirubin indicate a hepatocellular pattern of injury.</li>\r\n<li><strong>Autoimmune markers:</strong> Positive ANA and SMA, along with elevated IgG levels, strongly suggest AIH.</li>\r\n<li><strong>Hypergammaglobulinemia:</strong> A hallmark of AIH, reflecting the autoimmune nature of the disease.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Exclusion of Other Options:</strong>\r\n<ul>\r\n<li><strong>PBC (A):</strong> Typically presents with elevated alkaline phosphatase and positive antimitochondrial antibody (AMA). Not observed here.</li>\r\n<li><strong>PSC (C):</strong> Associated with biliary strictures seen on cholangiography and elevated ALP. Commonly coexists with inflammatory bowel disease.</li>\r\n<li><strong>NASH (D):</strong> Generally associated with metabolic syndrome, obesity, and ALT &gt; AST, none of which are present.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Diagnosis Confirmation:</strong>\r\n<ul>\r\n<li>The diagnosis of AIH can be confirmed with a <strong>liver biopsy</strong>, which typically shows <strong>interface hepatitis</strong> (lymphocytic infiltration at the portal-parenchymal interface).</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Management:</strong></p>\r\n<ul>\r\n<li><strong>Induction Therapy:</strong> Prednisone alone or in combination with azathioprine.</li>\r\n<li><strong>Maintenance Therapy:</strong> Azathioprine for long-term control.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Autoimmune hepatitis is a common cause of hepatocellular liver injury in young to middle-aged women, often associated with other autoimmune diseases.</li>\r\n<li>Early diagnosis and treatment are essential to prevent progression to cirrhosis.</li>\r\n</ul>\r\n",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">1-D, 2-A, 3-E, 4-C, 5-B</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-C, 3-D, 4-B, 5-E</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">1-E, 2-B, 3-A, 4-D, 5-C</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C, 2-D, 3-B, 4-A, 5-E</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\"><p>Match the following liver disorders with their characteristic laboratory findings:</p><p><strong>Disorders:</strong></p><ol><li><strong>Hemolysis/Gilbert&rsquo;s Syndrome</strong></li><li><strong>Acute Hepatocellular Necrosis</strong></li><li><strong>Chronic Hepatocellular Disorders</strong></li><li><strong>Alcoholic Hepatitis</strong></li><li><strong>Intra-/Extrahepatic Cholestasis</strong></li></ol><p><strong>Laboratory Findings:</strong></p><ol style=\"list-style-type: upper-alpha;\"><li><strong>Elevated ALT and AST &gt;500 IU, both bilirubin fractions elevated.</strong></li><li><strong>Elevated ALP (&gt;4x normal), normal albumin.</strong></li><li><strong>Elevated AST &gt;2, low albumin.</strong></li><li><strong>Normal ALP, indirect hyperbilirubinemia.</strong></li><li><strong>Elevated ALT &gt; AST, bilirubinemia.</strong></li></ol></span></p>",
      "unique_key": "DT1295173",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295173,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Hemolysis/Gilbert&rsquo;s Syndrome (1-D):</strong>\r\n<ul>\r\n<li>Normal ALP, indirect hyperbilirubinemia, and normal liver enzymes indicate Gilbert&rsquo;s syndrome or hemolysis.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Acute Hepatocellular Necrosis (2-A):</strong>\r\n<ul>\r\n<li>Marked elevation in ALT and AST (&gt;500 IU) with both bilirubin fractions elevated is consistent with acute hepatocellular necrosis.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Chronic Hepatocellular Disorders (3-E):</strong>\r\n<ul>\r\n<li>Mild elevation of ALT &gt; AST with bilirubinemia is typical of chronic liver disease.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Alcoholic Hepatitis (4-C):</strong>\r\n<ul>\r\n<li>Elevated AST ratio (&gt;2) with low albumin is the hallmark of alcoholic liver injury.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Intra-/Extrahepatic Cholestasis (5-B):</strong>\r\n<ul>\r\n<li>Elevated ALP (&gt;4&times; normal) with normal albumin is indicative of cholestasis or biliary obstruction.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Use ALT/AST ratios and levels to identify hepatocellular injuries.</li>\r\n<li>Elevated ALP indicates cholestasis, while indirect hyperbilirubinemia points to unconjugated causes (e.g., Gilbert&rsquo;s syndrome or hemolysis).</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501062a490e96-69ac-4e4c-9a20-9e9b948eb20d.jpg\">\r\n",
      "correct_choice_id": 71,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C, 2-D, 3-B, 4-A, 5-E</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-C, 3-E, 4-D, 5-B</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">1-E, 2-A, 3-C, 4-B, 5-D</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B, 2-E, 3-A, 4-C, 5-D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following hepatitis viruses with their respective characteristic features:<p><strong>Hepatitis Viruses:</strong></p><ol><li>Hepatitis A Virus (HAV)</li><li>Hepatitis B Virus (HBV)</li><li>Hepatitis C Virus (HCV)</li><li>Hepatitis D Virus (HDV)</li><li>Hepatitis E Virus (HEV)</li></ol><p><strong>Characteristic Features:</strong></p><ol style=\"list-style-type: upper-alpha;\"><li><strong>Defective RNA virus that requires HBV as a helper virus for replication.</strong></li><li><strong>Enveloped RNA virus associated with chronic liver disease and hepatocellular carcinoma.</strong></li><li><strong>Non-enveloped RNA virus transmitted fecal-orally, diagnosed by IgM anti-HAV.</strong></li><li><strong>Double-shelled DNA virus with HBsAg as a key marker.</strong></li><li><strong>Non-enveloped RNA virus transmitted via contaminated water, often self-limiting.</strong></li></ol></span></p>",
      "unique_key": "DT1295175",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295175,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Hepatitis A Virus (HAV - 1-C):</strong>\r\n<ul>\r\n<li>A non-enveloped, positive-sense RNA virus transmitted via the <strong>fecal-oral route</strong>.</li>\r\n<li>Diagnosed with <strong>IgM anti-HAV antibodies</strong> during acute infection.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Hepatitis B Virus (HBV - 2-D):</strong>\r\n<ul>\r\n<li>A <strong>double-shelled DNA virus</strong> with HBsAg as a critical diagnostic marker.</li>\r\n<li>Transmission occurs through blood, sexual contact, or perinatal exposure.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Hepatitis C Virus (HCV - 3-B):</strong>\r\n<ul>\r\n<li>An <strong>enveloped RNA virus</strong> associated with chronic liver disease and <strong>hepatocellular carcinoma (HCC)</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Hepatitis D Virus (HDV - 4-A):</strong>\r\n<ul>\r\n<li>A <strong>defective RNA virus</strong> that relies on <strong>HBV as a helper virus</strong> for replication.</li>\r\n<li>Diagnosed via <strong>anti-HDV antibodies and HDV RNA</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Hepatitis E Virus (HEV - 5-E):</strong>\r\n<ul>\r\n<li>A non-enveloped RNA virus transmitted through <strong>contaminated water</strong>, typically self-limiting but can be severe in <strong>pregnant women</strong>.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Hepatitis viruses differ by genome structure, transmission routes, and clinical outcomes.</li>\r\n<li>HAV and HEV are <strong>fecal-oral transmitted</strong>, while HBV, HCV, and HDV are <strong>parenterally transmitted</strong>.</li>\r\n<li>Chronic liver disease and hepatocellular carcinoma are features of HBV, HCV, and HDV infections.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501066d42975d-c8cb-4dbb-a2b7-10872179dbae.jpg\">\r\n",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">HBsAg is the first serologic marker to appear after exposure.</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-HBc IgM indicates acute hepatitis B infection.</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">The presence of anti-HBs indicates recovery and immunity.</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">HBeAg persists indefinitely in recovered individuals.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 35-year-old man presents with fatigue and jaundice. He reports a history of unprotected sexual contact 8 weeks ago. His laboratory tests reveal elevated ALT and positive HBsAg. Based on the timeline of serologic markers in hepatitis B infection, which of the following is a wrong statement?</span></p>",
      "unique_key": "DT1295177",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295177,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>HBsAg (Hepatitis B Surface Antigen):</strong>\r\n<ul>\r\n<li>HBsAg is the first detectable marker in acute hepatitis B infection and appears <strong>4-10 weeks</strong> after exposure.</li>\r\n<li>Its persistence beyond <strong>6 months</strong> indicates chronic infection.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Anti-HBc IgM (Hepatitis B Core Antibody):</strong>\r\n<ul>\r\n<li>Anti-HBc IgM is present during the acute phase and indicates recent infection.</li>\r\n<li>It transitions to IgG Anti-HBc in chronic or resolved infections.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Anti-HBs (Hepatitis B Surface Antibody):</strong>\r\n<ul>\r\n<li>Anti-HBs appears after the disappearance of HBsAg and indicates <strong>recovery and immunity</strong>. It is also a marker of successful vaccination.</li>\r\n</ul>\r\n</li>\r\n<li><strong>HBeAg (Hepatitis B e Antigen):</strong>\r\n<ul>\r\n<li>HBeAg is a marker of <strong>viral replication and infectivity</strong>.</li>\r\n<li>It does <strong>not persist indefinitely</strong> in recovered individuals; its clearance indicates reduced infectivity and often precedes seroconversion to anti-HBe.</li>\r\n</ul>\r\n</li>\r\n</ol><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106d65b0f47-c169-4e12-97e5-a24b4086cf97.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>HBeAg</strong> clearance is a critical marker in recovery or effective antiviral treatment.</li>\r\n<li><strong>Anti-HBs</strong> confirms immunity, either from infection recovery or vaccination.</li>\r\n<li>Persistence of HBsAg or HBeAg beyond 6 months suggests <strong>chronic infection</strong>.</li>\r\n</ul>\r\n",
      "correct_choice_id": 94,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">All adults aged 18-79 years.</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Persons with a history of injection drug use.</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Healthcare workers exposed to HCV-contaminated blood via needlestick injuries.</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">People with vasculitis.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following groups is NOT routinely recommended for hepatitis C virus (HCV) screening according to current guidelines?</span></p>",
      "unique_key": "DT1295178",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295178,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Current HCV Screening Guidelines:</strong>\r\n<ul>\r\n<li>Universal screening is recommended for <strong>all adults aged 18&ndash;79 years</strong>, regardless of risk factors.</li>\r\n<li>High-risk populations include:\r\n<ul>\r\n<li>Persons with a history of <strong>injection drug use</strong> (even if used only once).</li>\r\n<li>Healthcare workers exposed to <strong>HCV-contaminated blood</strong> (e.g., needlestick injuries).</li>\r\n<li>Persons with <strong>HIV infection</strong> or unexplained elevations in liver enzymes.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ol><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501061c7582cf-15bf-440c-b171-e44e173b4c68.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Universal screening for HCV is recommended for adults aged 18&ndash;79 and certain high-risk groups.</li>\r\n<li>Hepatitis A vaccination protects against HAV but does not influence HCV screening requirements.</li>\r\n</ul>\r\n",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute hepatitis B infection.</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic hepatitis B infection with low infectivity.</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Resolved past hepatitis B infection with immunity.</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Vaccination against hepatitis B.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old man presents for a routine health check-up. He has no significant past medical history but mentions a brief history of jaundice 3 years ago. He denies current symptoms, alcohol use, or high-risk behaviors. His hepatitis panel reveals the following:<ul><li><strong>HBsAg:</strong> Negative</li><li><strong>Anti-HBs:</strong> Positive</li><li><strong>Anti-HBc (IgG):</strong> Positive</li><li><strong>Anti-HBc (IgM):</strong> Negative</li><li><strong>HBeAg:</strong> Negative</li><li><strong>Anti-HBe:</strong> Positive</li></ul>What is the most likely interpretation of these findings?</span></p>",
      "unique_key": "DT1295179",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295179,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Serologic Markers Interpretation:</strong>\r\n<ul>\r\n<li><strong>HBsAg (Hepatitis B Surface Antigen): Negative</strong> &rarr; No active infection.</li>\r\n<li><strong>Anti-HBs (Antibodies to HBsAg): Positive</strong> &rarr; Indicates immunity.</li>\r\n<li><strong>Anti-HBc IgG (Antibodies to Core Antigen): Positive</strong> &rarr; Indicates past or ongoing infection.</li>\r\n<li><strong>Anti-HBc IgM (Antibodies to Core Antigen, IgM): Negative</strong> &rarr; Rules out recent acute infection.</li>\r\n<li><strong>HBeAg: Negative and Anti-HBe: Positive</strong> &rarr; Indicates resolution of viral replication and low or no infectivity.</li>\r\n</ul></li>\r\n<li><strong>Differential Diagnoses Based on Findings:</strong>\r\n<ul>\r\n<li><strong>Acute hepatitis B (Option A):</strong> Would show positive HBsAg and anti-HBc IgM.</li>\r\n<li><strong>Chronic hepatitis B (Option B):</strong> Would show persistent HBsAg, anti-HBc IgG, and possibly HBeAg.</li>\r\n<li><strong>Vaccination against hepatitis B (Option D):</strong> Anti-HBs is positive, but Anti-HBc (both IgG and IgM) would be negative since vaccination does not induce antibodies to core antigens.</li>\r\n</ul></li>\r\n<li><strong>Final Diagnosis:</strong>\r\n<ul>\r\n<li>The findings are consistent with <strong>resolved past hepatitis B infection</strong> and immunity.</li>\r\n</ul>\r\n</li>\r\n</ol><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501065ce9000b-3b71-455d-86dc-feeb0d157a43.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>HBsAg:</strong> Marker of active infection (acute or chronic).</li>\r\n<li><strong>Anti-HBs:</strong> Marker of immunity (recovery or vaccination).</li>\r\n<li><strong>Anti-HBc IgG:</strong> Marker of past or chronic infection.</li>\r\n<li><strong>Anti-HBc IgM:</strong> Marker of acute infection.</li>\r\n<li><strong>HBeAg/Anti-HBe:</strong> Helps differentiate infectivity status in active or resolved infections.</li>\r\n</ul>\r\n",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-A, 3-B, 4-C</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B, 2-B, 3-A, 4-C</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-B, 3-C, 4-A</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C, 2-A, 3-B, 4-A</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following vaccines with the type of viral hepatitis they prevent.<p><strong>Vaccines:</strong></p><ol><li><strong>Havrix</strong></li><li><strong>Vaqta</strong></li><li><strong>Engerix</strong></li><li><strong>Twinrix</strong></li></ol><p><strong>Type of Viral Hepatitis:</strong></p><ol style=\"list-style-type: upper-alpha;\"><li>Hepatitis A</li><li>Hepatitis B</li><li>Both Hepatitis A and B</li></ol></span></p>",
      "unique_key": "DT1295180",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295180,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Havrix (1-A):</strong>\r\n<ul>\r\n<li>Designed to prevent <strong>Hepatitis A</strong>. Administered in a two-dose series.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Vaqta (2-A):</strong>\r\n<ul>\r\n<li>Prevents <strong>Hepatitis A</strong>, with a similar dosing schedule to Havrix.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Engerix-B (3-B):</strong>\r\n<ul>\r\n<li>A vaccine for <strong>Hepatitis B</strong>, administered in a three-dose series.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Twinrix (4-C):</strong>\r\n<ul>\r\n<li>A combination vaccine providing protection against <strong>both Hepatitis A and B</strong>.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Havrix and Vaqta:</strong> Specific to Hepatitis A.</li>\r\n<li><strong>Engerix-B:</strong> Protects against Hepatitis B.</li>\r\n<li><strong>Twinrix:</strong> Offers dual protection against Hepatitis A and B, suitable for travelers or high-risk individuals.</li>\r\n</ul>\r\n",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Amiodarone</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Tamoxifen</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Valproic Acid</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old male with obesity and type 2 diabetes presents with fatigue and progressive elevation of liver enzymes. An ultrasound reveals fatty liver. His medications include:<ul><li><strong>Amiodarone</strong> for arrhythmia.</li><li><strong>Methotrexate</strong> for rheumatoid arthritis.</li><li><strong>Tamoxifen</strong> for a history of breast cancer.</li><li><strong>Valproic acid</strong> for epilepsy.</li></ul>Laboratory workup reveals ALT 120 IU/L, AST 110 IU/L, and no evidence of viral hepatitis or autoimmune liver disease.<br>Which one of the following medications is most likely contributing to his progressive fatty liver and should be discontinued first?</span></p>",
      "unique_key": "DT1295181",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295181,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Amiodarone:</strong>\r\n<ul>\r\n<li>Amiodarone is a leading cause of drug-induced fatty liver. It results in <strong>macrovesicular and microvesicular steatosis</strong> due to mitochondrial dysfunction and impaired fatty acid oxidation.</li>\r\n<li>Progression to <strong>steatohepatitis</strong> is common if not discontinued.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Methotrexate:</strong>\r\n<ul>\r\n<li>While methotrexate can also cause steatosis, it typically results in <strong>fibrosis</strong> after long-term use rather than immediate progression to fatty liver.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Tamoxifen:</strong>\r\n<ul>\r\n<li>Tamoxifen is associated with <strong>macrovesicular steatosis</strong>, but the risk is lower compared to amiodarone and valproic acid.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Valproic Acid:</strong>\r\n<ul>\r\n<li>Valproic acid induces <strong>microvesicular steatosis</strong>, primarily through mitochondrial toxicity, but amiodarone&rsquo;s effects on the liver are generally more severe and widespread.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Management Plan:</strong></p>\r\n<ul>\r\n<li><strong>First Step:</strong> Discontinue amiodarone and consult the treating physician for alternative therapies.</li>\r\n<li>Evaluate the necessity of other medications contributing to fatty liver (e.g., methotrexate, tamoxifen, valproic acid).</li>\r\n<li>Initiate lifestyle interventions to address underlying NAFLD.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Amiodarone</strong> is the most hepatotoxic among the listed medications for inducing fatty liver.</li>\r\n<li>Discontinuing or substituting drugs should always involve weighing benefits and risks in consultation with specialists.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501064f732fbf-85c7-4d4d-a7b0-52be30068517.jpg\">\r\n",
      "correct_choice_id": 132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Immediate liver transplantation.</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Start corticosteroid therapy.</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Perform liver biopsy for confirmation.</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Initiate pentoxifylline therapy.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old man presents to the emergency department with fatigue, jaundice, and abdominal discomfort. He has a history of consuming 10-12 beers daily for the past 20 years. Physical examination reveals palmar erythema (as shown in the image), scleral icterus, hepatomegaly, and ascites. Laboratory results are as follows:<ul><li><strong>AST:</strong> 210 IU/L</li><li><strong>ALT:</strong> 95 IU/L</li><li><strong>Bilirubin (total):</strong> 8.5 mg/dL</li><li><strong>Albumin:</strong> 2.6 g/dL</li><li><strong>INR:</strong> 2.1</li><li><strong>(MDF):</strong> 54 (maddrey&rsquo;s)</li></ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010652da3e17-90ae-4621-954e-fc8e09558142.jpg\"><br>What is the next best step in the management of this patient?</span></p>",
      "unique_key": "DT1295182",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295182,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Key Clinical Features:</strong>\r\n<ul>\r\n<li>History of <strong>chronic alcohol use</strong>.</li>\r\n<li>Physical findings such as <strong>palmar erythema</strong>, jaundice, hepatomegaly, and ascites.</li>\r\n<li>Laboratory evidence of hepatocellular damage with <strong>AST &gt; ALT</strong> (typical for alcoholic hepatitis), hyperbilirubinemia, and prolonged INR.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Maddrey&rsquo;s Discriminant Function (DF):</strong>\r\n<ul>\r\n<li>Formula: DF = 4.6 &times; (Prothrombin time prolongation) + Serum bilirubin (mg/dL).</li>\r\n<li>DF &gt; 32 indicates <strong>severe alcoholic hepatitis</strong>, where corticosteroid therapy (e.g., prednisolone) is recommended unless contraindicated.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Options Explained:</strong>\r\n<ul>\r\n<li><strong>A. Immediate liver transplantation:</strong> Not the first-line management. Patients with ongoing alcohol use are generally not candidates for transplantation.</li>\r\n<li><strong>C. Liver biopsy:</strong> May confirm diagnosis but is not routinely performed unless the clinical picture is unclear or alternative diagnoses are suspected.</li>\r\n<li><strong>D. Pentoxifylline:</strong> Previously used in severe alcoholic hepatitis but is now less favored compared to corticosteroids.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Management Plan:</strong></p>\r\n<ol>\r\n<li><strong>Corticosteroid Therapy:</strong>\r\n<ul>\r\n<li>Prednisolone 40 mg daily for 28 days improves survival in severe alcoholic hepatitis (DF &gt;32).</li>\r\n<li>Response can be monitored using the <strong>Lille score</strong> after 7 days.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Supportive Care:</strong>\r\n<ul>\r\n<li>Nutritional support, abstinence from alcohol, and management of complications (e.g., ascites, encephalopathy).</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Alcoholic hepatitis is characterized by <strong>AST </strong><strong>&gt; 2</strong>, elevated bilirubin, and prolonged INR.</li>\r\n<li><strong>Severe cases (DF &gt; 32)</strong> warrant corticosteroid therapy unless contraindicated.</li>\r\n<li>Early recognition and intervention improve outcomes.</li>\r\n</ul>\r\n",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Repeat endoscopic therapy with beta-blockers as secondary prophylaxis.</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Immediate evaluation for liver transplantation.</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Transjugular intrahepatic portosystemic shunt (TIPS).</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Surgical shunt placement.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old man with a history of liver cirrhosis secondary to chronic hepatitis C presents with recurrent hematemesis. He was previously managed with band ligation for esophageal varices. On admission, his vitals are stable, but laboratory tests reveal the following:<ul><li><strong>INR:</strong> 2.1</li><li><strong>Albumin:</strong> 2.6 g/dL</li><li><strong>Bilirubin:</strong> 3.8 mg/dL</li><li><strong>Child-Pugh Score:</strong> 9 (Class B).</li></ul>Endoscopy confirms recurrent esophageal variceal bleeding. Pharmacologic therapy with octreotide and prophylactic antibiotics has been initiated.<br>What is the most appropriate next step in the management of this patient?</span></p>",
      "unique_key": "DT1295183",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295183,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Key Clinical Features:</strong>\r\n<ul>\r\n<li>The patient has recurrent esophageal variceal bleeding and decompensated cirrhosis (Child-Pugh Class B).</li>\r\n<li>Despite prior band ligation, the recurrence indicates a failure of conventional secondary prophylaxis, making <strong>TIPS</strong> the next best option.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Management Pathway for Recurrent Variceal Bleeding:</strong>\r\n<ul>\r\n<li><strong>First-line therapy:</strong> Endoscopic therapy (e.g., band ligation) combined with pharmacologic therapy (e.g., nonselective beta-blockers).</li>\r\n<li><strong>TIPS:</strong> Indicated for refractory or recurrent bleeding, especially in decompensated cirrhosis. It reduces portal pressure and decreases the risk of future bleeding.</li>\r\n</ul>\r\n</li>\r\n</ol><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010690c70c7f-f851-4402-8e02-db976cd6c3df.jpg\">\r\n<ol start=\"3\">\r\n<li><strong>Incorrect Option:</strong>\r\n<ul>\r\n<li><strong>A. Repeat Endoscopic Therapy with Beta-Blockers:</strong> Useful in compensated cirrhosis or early recurrence but insufficient for refractory cases in decompensated cirrhosis.</li>\r\n<li><strong>B. Immediate Evaluation for Liver Transplantation:</strong> Transplantation may be required eventually but is not an immediate solution for acute bleeding.</li>\r\n<li><strong>D. Surgical Shunt Placement:</strong> Rarely used due to higher morbidity and mortality compared to TIPS.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>TIPS</strong> is the preferred intervention for <strong>refractory variceal bleeding</strong>, especially in patients with decompensated cirrhosis.</li>\r\n<li>Liver transplantation evaluation should follow in patients with poor liver function.</li>\r\n<li>Combining pharmacologic therapy with endoscopic therapy remains the first-line approach for variceal bleeding.</li>\r\n</ul>\r\n",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">1 &rarr; 2 &rarr; 3 &rarr; 5 &rarr; 4</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">1 &rarr; 2 &rarr; 5 &rarr; 4 &rarr; 3</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">1 &rarr; 2 &rarr; 5 &rarr; 3 &rarr; 4</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">2 &rarr; 1 &rarr; 5 &rarr; 4 &rarr; 3</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\"><p>A 60-year-old man with a history of alcohol-related cirrhosis presents with abdominal distension and shortness of breath. On examination, he has tense ascites and peripheral edema. His vitals are stable, but his laboratory findings reveal the following:</p><ul><li>Serum albumin: 2.1 g/dL</li><li>Serum sodium: 130 mmol/L</li><li>Serum creatinine: 1.5 mg/dL</li></ul><p>Ultrasound confirms moderate ascites without signs of infection or portal vein thrombosis.<br />Arrange the following pathological events in the correct sequence leading to ascites formation in cirrhosis:</p><ol><li>Portal hypertension develops.</li><li>Splanchnic vasodilation occurs.</li><li>Sodium retention increases due to activation of vasoconstrictors.</li><li>Increased lymph formation and ascites development.</li><li>Arterial underfilling triggers activation of antinatriuretic systems.</li></ol></span></p>",
      "unique_key": "DT1295184",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295184,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Step 1: Portal Hypertension Develops (1)</strong>\r\n<ul>\r\n<li>Portal hypertension is the initiating factor in cirrhosis-related ascites. It results from increased resistance to blood flow within the liver.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Step 2: Splanchnic Vasodilation (2)</strong>\r\n<ul>\r\n<li>Portal hypertension triggers <strong>splanchnic vasodilation</strong>, leading to reduced effective arterial blood volume despite increased total blood volume.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Step 3: Arterial Underfilling and Activation of Antinatriuretic Systems (5)</strong>\r\n<ul>\r\n<li>Arterial underfilling due to vasodilation activates compensatory systems, such as the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system, and antidiuretic hormone (ADH), promoting <strong>sodium and water retention</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Step 4: Sodium Retention Increases (3)</strong>\r\n<ul>\r\n<li>The activated RAAS and ADH systems result in <strong>sodium retention</strong>, causing plasma volume expansion.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Step 5: Increased Lymph Formation and Ascites Development (4)</strong>\r\n<ul>\r\n<li>The elevated splanchnic pressure increases capillary permeability, leading to <strong>lymph formation and ascites development</strong>.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Ascites in cirrhosis results from a cascade starting with <strong>portal hypertension</strong>, followed by <strong>vasodilation, sodium retention, and lymph accumulation</strong>.</li>\r\n<li>Management includes <strong>sodium restriction</strong>, diuretics, and large-volume paracentesis if necessary.</li>\r\n</ul>\r\n",
      "correct_choice_id": 163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Active, untreated sepsis</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Cholangiocarcinoma not fitting into transplant protocols</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Uncontrolled psychiatric disorder with ongoing medical noncompliance</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">HIV infection with CD4 count <100/&mu;L and uncontrolled viremia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is NOT an absolute contraindication for liver transplantation?</span></p>",
      "unique_key": "DT1295185",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295185,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Absolute Contraindications for Liver Transplantation:</strong>\r\n<ul>\r\n<li><strong>Active, untreated sepsis (A):</strong> Sepsis must be controlled before transplantation to prevent fatal postoperative infections.</li>\r\n<li><strong>Cholangiocarcinoma not fitting into transplant protocols (B):</strong> Cholangiocarcinoma outside of transplant protocols is considered an absolute contraindication due to poor survival rates.</li>\r\n<li><strong>HIV with CD4 &lt;100/&mu;L (D):</strong> Severe immunosuppression and uncontrolled HIV viremia are absolute contraindications due to high risk of perioperative complications and poor prognosis.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Uncontrolled Psychiatric Disorders (C):</strong>\r\n<ul>\r\n<li>This is a <strong>relative contraindication</strong>, not absolute. While it poses challenges (e.g., compliance with medications), psychiatric disorders can often be managed with appropriate support and intervention to allow transplantation.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Absolute contraindications involve <strong>medical conditions</strong> or <strong>malignancies</strong> that preclude safe or effective transplantation.</li>\r\n<li><strong>Psychiatric disorders</strong>, though challenging, are not absolute contraindications and may be addressed with multidisciplinary care.</li>\r\n</ul>\r\n",
      "correct_choice_id": 173,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">1-D, 2-B, 3-C, 4-A</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-D, 3-B, 4-C</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B, 2-A, 3-D, 4-C</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C, 2-D, 3-B, 4-A</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following liver status scores with their respective uses and components.<p><strong>Scores:</strong></p><br>1. Child-Turcotte-Pugh (CTP) Score<br>2. Model for End-Stage Liver Disease (MELD) Score<br>3. Lille Score<br>4. Maddrey's Discriminant Function (DF)<p><strong>Uses and Components:</strong></p>A. Assesses prognosis in alcoholic hepatitis; includes bilirubin and prothrombin time.<br>B. Predicts survival in cirrhosis and prioritizes liver transplantation; based on bilirubin, INR, and creatinine.<br>C. Assesses response to corticosteroids in severe alcoholic hepatitis; calculated after 7 days of therapy.<br>D. Evaluates liver function in cirrhosis; based on bilirubin, albumin, INR, ascites, and encephalopathy.</span></p>",
      "unique_key": "DT1295186",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295186,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Child-Turcotte-Pugh (CTP) Score (1-D):</strong>\r\n<ul>\r\n<li><strong>Use:</strong> Assesses liver function and prognosis in cirrhosis.</li>\r\n<li><strong>Components:</strong> Bilirubin, albumin, INR, ascites, and encephalopathy.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Model for End-Stage Liver Disease (MELD) Score (2-B):</strong>\r\n<ul>\r\n<li><strong>Use:</strong> Predicts mortality and prioritizes liver transplant candidates.</li>\r\n<li><strong>Components:</strong> Bilirubin, INR, creatinine, and sodium (recently added in MELD-Na).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Lille Score (3-C):</strong>\r\n<ul>\r\n<li><strong>Use:</strong> Evaluates response to corticosteroids in severe alcoholic hepatitis.</li>\r\n<li><strong>Components:</strong> Includes bilirubin levels before and after 7 days of corticosteroid therapy.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Maddrey&rsquo;s Discriminant Function (DF) (4-A):</strong>\r\n<ul>\r\n<li><strong>Use:</strong> Assesses prognosis in alcoholic hepatitis.</li>\r\n<li><strong>Components:</strong> Bilirubin and prothrombin time (PT). A DF &gt;32 indicates severe disease.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>The <strong>CTP score</strong> is widely used for grading cirrhosis and assessing the need for TIPS or transplant.</li>\r\n<li>The <strong>MELD score</strong> prioritizes liver transplantation.</li>\r\n<li>The <strong>Lille score</strong> is critical in adjusting corticosteroid therapy in alcoholic hepatitis.</li>\r\n<li><strong>Maddrey&rsquo;s DF</strong> identifies severe alcoholic hepatitis requiring steroids.</li>\r\n</ul>\r\n",
      "correct_choice_id": 181,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Cholecystitis</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Ruptured ectopic pregnancy</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Perforated peptic ulcer</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Postoperative hypocalcemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old woman presents with severe epigastric pain radiating to her back. Laboratory tests reveal elevated serum amylase levels. Which of the following conditions is NOT a recognized cause of hyperamylasemia?</span></p>",
      "unique_key": "DT1295187",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295187,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Hyperamylasemia:</strong></p>\r\n<ul>\r\n<li>Hyperamylasemia refers to elevated serum amylase levels, commonly associated with conditions that involve pancreatic or gastrointestinal injury.</li>\r\n<li>It may also occur in extrapancreatic conditions such as biliary tract disease, intraabdominal infections, or systemic inflammation.</li>\r\n</ul>\r\n<p><strong> Explanation of Each Option:</strong></p>\r\n<ol>\r\n<li><strong> Cholecystitis:</strong>\r\n<ul>\r\n<li><strong>Cause of Hyperamylasemia:</strong>\r\n<ul>\r\n<li>Inflammation of the gallbladder (acute cholecystitis) can lead to secondary pancreatic enzyme elevation due to biliary obstruction or inflammation.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Clinical Features:</strong>\r\n<ul>\r\n<li>Right upper quadrant pain, fever, and positive Murphy&rsquo;s sign.</li>\r\n<li>Hyperamylasemia is often mild in these cases.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li><strong> Ruptured Ectopic Pregnancy:</strong>\r\n<ul>\r\n<li><strong>Cause of Hyperamylasemia:</strong>\r\n<ul>\r\n<li>Rupture of an ectopic pregnancy causes intraperitoneal bleeding and inflammation, which may indirectly elevate amylase levels.</li>\r\n<li>This is termed \"salivary-type\" amylase elevation, rather than pancreatic.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Clinical Features:</strong>\r\n<ul>\r\n<li>Sudden onset lower abdominal pain, vaginal bleeding, and hypotension in a patient of childbearing age.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li><strong> Perforated Peptic Ulcer:</strong>\r\n<ul>\r\n<li><strong>Cause of Hyperamylasemia:</strong>\r\n<ul>\r\n<li>Perforation leads to peritoneal irritation, which can elevate amylase levels due to peritoneal absorption of amylase from the gastrointestinal tract.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Clinical Features:</strong>\r\n<ul>\r\n<li>Severe epigastric pain, signs of peritonitis, and history of peptic ulcer disease.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li><strong> Postoperative Hypocalcemia (Correct Answer):</strong>\r\n<ul>\r\n<li><strong>Not a Cause of Hyperamylasemia:</strong>\r\n<ul>\r\n<li>Hypocalcemia does not lead to elevated amylase levels and is unrelated to pancreatic or peritoneal inflammation.</li>\r\n<li>Postoperative hypocalcemia is more commonly seen in thyroid/parathyroid surgeries due to parathyroid injury or calcium metabolism disorders.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ol><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010679ee7369-ed17-46b3-9cee-62a0311c8c47.jpg\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106a65d2ccc-59c4-4fba-85e9-221e004e108a.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Recognized Causes of Hyperamylasemia:</strong>\r\n<ul>\r\n<li>Pancreatic conditions (e.g., acute pancreatitis).</li>\r\n<li>Biliary tract diseases (e.g., cholecystitis, choledocholithiasis).</li>\r\n<li>Intraabdominal conditions causing inflammation or rupture (e.g., perforated ulcers, ectopic pregnancy).</li>\r\n</ul></li>\r\n<li><strong>Unrelated Conditions:</strong> Postoperative hypocalcemia or purely metabolic abnormalities do not cause hyperamylasemia.</li>\r\n</ul>\r\n",
      "correct_choice_id": 194,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}